Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Bial - Portela C S.A.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01227655CT.gov Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. | — | Completed | — | — | — |
NCT01568073CT.gov Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon | — | Completed | — | — | — |
NCT01568047CT.gov Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients | — | Completed | — | — | — |
NCT02169414CT.gov Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics | — | Completed | — | — | — |
NCT01568034CT.gov A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 | — | Completed | — | — | — |
NCT01533116CT.gov Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Benserazide (this asset) | Bial - Portela C S.A. | P3 | BB · 69 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Other indications for Benserazide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Beta-Thalassemia Intermedia | — | P1/2 | CCC · 48 |
| Sickle Cell Disease | — | P1/2 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Benserazide in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/benserazide-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →